Originally published In Press as doi:10.1074/jbc.M107623200 on January 11, 2002
J. Biol. Chem., Vol. 277, Issue 13, 10775-10782, March 29, 2002
Keratin 8 Phosphorylation by p38 Kinase Regulates Cellular
Keratin Filament Reorganization
MODULATION BY A KERATIN 1-LIKE DISEASE-CAUSING MUTATION*
Nam-On
Ku
,
Salman
Azhar¶, and
M. Bishr
Omary§
From the Department of Medicine, and ¶ Geriatric
Research, Education and Clinical Center, Veterans Affairs Palo Alto
Health Care System, Palo Alto, California 94304 and the Digestive
Disease Center, Stanford University School of Medicine,
Stanford, California 94305
Received for publication, August 9, 2001, and in revised form, December 27, 2001
 |
ABSTRACT |
Keratin 8 (K8) serine 73 occurs within a
relatively conserved type II keratin motif
(68NQSLLSPL) and becomes phosphorylated in cultured
cells and organs during mitosis, cell stress, and apoptosis. Here we
show that Ser-73 is exclusively phosphorylated in vitro by
p38 mitogen-activated protein kinase. In cells, Ser-73 phosphorylation
occurs in association with p38 kinase activation and is inhibited by
SB203580 but not by PD98059. Transfection of K8 Ser-73
Ala or K8
Ser-73
Asp with K18 generates normal-appearing filaments. In
contrast, exposure to okadaic acid results in keratin filament
destabilization in cells expressing wild-type or Ser-73
Asp K8,
whereas Ser-73
Ala K8-expressing cells maintain relatively stable
filaments. p38 kinase associates with K8/18 immunoprecipitates and
binds selectively with K8 using an in vitro overlay assay.
Given that K1 Leu-160
Pro (157NQSLLQPL
157NQSPLQPL) leads to epidermolytic hyperkeratosis, we
tested and showed that the analogous K8 Leu-71
Pro leads to K8
hyperphosphorylation by p38 kinase in vitro and in
transfected cells, likely due to Ser-70 neo-phosphorylation, in
association with significant keratin filament collapse upon cell
exposure to okadaic acid. Hence, K8 Ser-73 is a physiologic
phosphorylation site for p38 kinase, and its phosphorylation plays an
important role in keratin filament reorganization. The Ser-73
Ala-associated filament reorganization defect is rescued by a Ser-73
Asp mutation. Also, disease-causing keratin mutations can modulate
keratin phosphorylation and organization, which may affect disease pathogenesis.
 |
INTRODUCTION |
The "soft" mucosal keratins
(K)1 make up the intermediate
filament (IF) proteins that are preferentially expressed in epithelial cells that line the inner and outer surfaces of animal tissues. These
mucosal keratins consist of a large family (at least 20 members termed
K1 to K20) of cytoplasmic proteins that are divided into relatively
acidic type I (K9 to K20, pI < 6) and relatively basic type II
(K1 to K8, pI
6) keratins (1-4). Epithelial cells generally
express two or more keratin noncovalent heteropolymers in a 1:1 molar
ratio of type I to II IFs, with an epithelial cell type-specific unique
keratin complement. For example, single layered "simple type"
epithelia express K8 and K18, with variable levels of K19 and K20
depending on the cell type, whereas keratinocytes express K5/14 or
K1/10 basally and suprabasally, respectively. The prototype structure
of all IF proteins, including keratins, consists of a central
coiled-coil
-helix domain termed the "rod" that is flanked by
non-
-helical N-terminal "head" and C-terminal "tail" domains
(5, 6). Notably, the head and tail domains of keratins contain most of
the structural heterogeneity among IF proteins and also include the
domains that undergo phosphorylation. This distribution
correlation and other accumulating data (7-11) strongly suggest that
phosphorylation plays an important role in regulating the
tissue-specific functional roles of the large keratin family.
Although spectacular gains have been made in linking 14 of the more
than 20 keratins to a number of skin, oral, esophageal, and liver
diseases (12-17), full appreciation of keratin and other IF protein
function has been lagging. For some keratins, one clearly delineated
function is to protect cells from mechanical and nonmechanical forms of
injury, but how this occurs remains poorly understood (11, 12, 18, 19).
Regardless, an intact keratin filament network and how keratin
filaments are organized appear to be important effectors of this
ability to maintain cellular integrity. This is borne out by many
in vitro studies that correlated the importance of various
keratin domains to form typical-appearing filaments and by the
phenotypes that have been observed in patients with keratin diseases
and in animal models that express different keratin mutants (11, 13,
15-17, 19, 20). Although perturbations within the highly conserved
proximal and distal ends of the rod domain (which harbor most of the
described disease-causing keratin mutations but lack any evidence of
phosphorylation (10, 15)) have significant effects on filament
organization in vivo and in vitro, keratin
phosphorylation within the head and tail domains also plays a
significant role in filament organization in vitro (8, 21)
and in vivo (9, 10). In addition, keratin mutations within
the head domains, which may modulate keratin phosphorylation, have been
described. For example, mutations have been described that either
introduce a new potential phosphorylation site (e.g. K1 157NQSLLQP
157NQSPLQP which renders Ser-159 a potential
proline-directed kinase phosphorylation site (22)) or remove possible
phosphorylation sites (e.g. Ref. 23).
Keratin phosphorylation has been most extensively studied in K8/18/19
(10), due in part to the relative solubility of these keratins as
compared with epidermal keratins (24). These studies resulted in the
identification of several phosphorylation-mediated K8/18 functions. For
example, K18 Ser-33 phosphorylation regulates keratin binding to the
14-3-3 family of proteins during mitosis, which in turn plays a role in
keratin filament organization and solubility (25, 26). A direct role
for keratin phosphorylation may also occur, as noted for K19, whereby
mutation of its major phosphorylation site (Ser-35
Ala) altered
keratin filament organization in transiently transfected cells (27). In
addition, transgenic mouse studies showed that K18 Ser-52
phosphorylation facilitates a protective role against hepatotoxic
injury (28), a finding that has provided direct evidence for a number
of correlative data that document increased keratin phosphorylation in
association with a variety of stresses in cultured cells and in intact
animals (29). In the case of human K8, three major in vivo
phosphorylation sites have been identified: Ser-23, Ser-431, and
Ser-73. Ser-23 is a highly conserved site among all type II keratins,
which suggests a common keratin function for this modification, whereas
Ser-431 is a basally phosphorylated site that increases its
phosphorylation specific activity during mitosis and upon exposure to
epidermal growth factor in association with filament reorganization
(30). In contrast K8 Ser-73 phosphorylation behaves like an on/off
switch in cultured cells and in tissues, with phosphorylation being
"on" during mitosis, a variety of cell stresses including heat and drug exposure, and during apoptosis (31).
Although the function of K8 Ser-73 phosphorylation was unknown, our
hypothesis prior to embarking on this study was that its phosphorylation is likely to be important due to its on/off property and its association with important cell processes. Here we show that
the mitogen-activated protein kinase (MAPK) p38 (reviewed in Refs.
32-35) is a physiologic kinase for K8 Ser-73 phosphorylation, and we
demonstrate that K8 Ser-73 phosphorylation plays a significant role in
keratin filament reorganization in response to the phosphatase inhibitor okadaic acid. Since K8 Ser-73 is proximal to a human disease
mutation site in epidermal K1 (NQSLLQPL
NQSPLQPL, Ref. 22; with K8 Ser-73 being part of the motif
68NQSLLSPL of K8), we generated the equivalent
K1 mutation in K8 (i.e. NQSLLSPL
NQSPLSPL) and showed that it increased K8 phosphorylation,
as compared with wild-type K8. This skin disease-causing mutation also
resulted in significant keratin filament collapse in the presence of
okadaic acid. Therefore, K8 Ser-73 phosphorylation plays an important
role in modulating keratin filament reorganization. In addition, this
is the first demonstration that human keratin disease-causing mutations
can indeed result in keratin hyperphosphorylation and that such
hyperphosphorylation can affect keratin filament organization, which in
turn may contribute to disease pathogenesis.
 |
EXPERIMENTAL PROCEDURES |
Antibodies and Reagents--
The antibodies (Ab) used are as
follows: L2A1 mouse monoclonal antibody (mAb) that recognizes human K18
(24); mAb LJ4 that recognizes K8 Ser(P)-73 (31); mAb 5B3 that
recognizes K8 Ser(P)-431 (30); rabbit Ab 8250 that recognizes K18
Ser(P)-33 (26); rabbit Ab 3055 that recognizes K18 Ser(P)-52 (36); mAb
M20 (NeoMarkers; Freemont, CA) that recognizes K8; and anti-FLAG
antibody (Sigma). Other reagents used are as follows: anisomycin (An);
Empigen BB (Emp); p42 kinase; c-Jun N-terminal kinase (JNK); p38 kinase
(Calbiochem-Novabiochem); methyl methanesulfonate (MMS) (Aldrich);
PD98059, anti-p38, and anti-phospho-p38 antibodies (New England
Biolabs, Beverly, MA); SB203580 (kindly provided by Dr. John Lee,
SmithKline Beecham Pharmaceuticals, King of Prussia, PA);
orthophosphate (32PO4); and
[
-32P]ATP (PerkinElmer Life Sciences).
Cell Culture--
HT-29 (human colon), BHK (hamster
kidney), and NIH-3T3 (mouse fibroblast) cells were obtained from the
American Type Culture Collection (Manassas, VA) and cultured as
recommended by the supplier. To activate p38 kinase, cells were
incubated with An (10 µg/ml, 0-20 h) or with MMS (0.1 or 1 mg/ml,
0-24 h). Cells were then solubilized with 2% SDS-containing sample
buffer (37) followed by shearing of the DNA with a 27-gauge needle and
then boiling for 2 min to generate a total cell lysate. Alternatively,
cells were processed for immunoprecipitation as described below. For the kinase inhibitors SB203580 (p38 kinase) and PD98059 (MAPK kinase),
cells were preincubated with these compounds (20 and 100 µM, respectively) for 1 h and then treated with An
for 2 h.
Immunofluorescence Staining--
Transiently transfected cells
were grown on coverslips and fixed 3 days after transfection, using
100% methanol (
20 °C) for 3 min. Staining was done as described
(26). For okadaic acid (OA) treatment, OA (1 µg/ml) was added to the
transfected cells for 2 h before fixation and processing.
Fluorescence was analyzed using a Bio-Rad MRC1024 confocal laser
scanning and a Nikon TE300 inverted microscope. Cells co-transfected
with WT K18 and one of the four K8 constructs (WT, S73A, S73D, or L71P)
were scored, after treatment with OA, based on their filament
organization as follows: (i) cells with residual filaments, (ii) cells
with fine dots but without any residual filaments, and (iii) cells with
large dots.
Cell Transfection and cDNA Constructs--
The K8 mutants K8
Ser-73
Ala (S73A), S73D, and L71P were generated using a
TransformerTM mutagenesis kit (CLONTECH
Laboratories Inc., Palo Alto, CA) as recommended by the supplier.
Wild-type (WT) K8, WT K18, or mutant K8 cDNAs were subcloned into
the pMRB101 mammalian expression vector under control of the hCMV
promoter. The FLAG-tagged
-isoform of WT p38 or p38 AF
(kinase-inactive form due to double mutation at the phosphorylation
sites, T180A and Y182F; Ref. 38) were used to overexpress the p38
proteins in BHK cells with keratin constructs. Transient transfections
into NIH-3T3 or BHK cells were done using LipofectAMINE as recommended
by the supplier. The NIH-3T3 cells were used for immunofluorescence
experiments because they provided a well formed keratin
filament-staining pattern, whereas BHK cells were used to generate
keratins for the biochemical experiments since they had a higher
transfection efficiency.
Biochemical Methods--
Immunoprecipitation was carried out by
solubilizing cells with 1% Emp (1 h, 4 °C) in buffer A
(phosphate-buffered saline (PBS) (pH 7.4) containing 5 mM
EDTA, 0.1 mM phenylmethanesulfonyl fluoride, 10 µM pepstatin, 10 µM leupeptin, 25 µg/ml
aprotinin, and 1 µg/ml OA) or by solubilizing cells with 1% Nonidet
P-40 in buffer A. After pelleting (15 min; 16,000 × g), keratins were immunoprecipitated from the supernatant
using Sepharose-conjugated L2A1 followed by washing, analysis by
SDS-PAGE (37), and then staining with Coomassie Blue. For
immunoblotting, gels were transferred to membranes followed by blotting
(39) with individual anti-keratin antibodies. Bound antibodies were
visualized with peroxidase-conjugated secondary antibodies and enhanced
chemiluminescence. Two-dimensional chymotryptic phosphopeptide mapping
was carried out exactly as described (30, 40) using electrophoresis in
the first (horizontal) dimension and chromatography in the second
(vertical) dimension.
The overlay assay was performed as described (41) with minor
modifications. Briefly, total lysate and K8/18 immunoprecipitates from
HT-29 cells were analyzed using SDS-PAGE followed by transfer to a
polyvinylidene difluoride membrane (4 °C). The membrane was blocked
with 3% BSA in PBS for 2 days, followed by incubation with 1 µg/ml
p38 kinase in PBS with 0.05% Tween and 0.1% BSA for 2 h
(22 °C). After washing, the membrane was incubated with anti-p38 antibody for immunoblotting.
In Vivo and in Vitro 32P Labeling--
In
vitro kinase reactions were carried out using K8/18
immunoprecipitates. For each of the kinases used (p38, p42, and Jun kinases), the buffers provided by the supplier were used as
recommended. Immunoprecipitates of K8/18 were washed two times with the
respective kinase buffer (in addition to the routine washings as part
of immunoprecipitation) and then incubated with 5 µCi of
[
-32P]ATP, the kinase, and 20 µM ATP (10 min in a total volume of 25 µl). The kinase reaction was quenched by
adding 4 times the normal concentration of Laemmli sample buffer,
followed by boiling for 90 s and then analysis by SDS-PAGE and
autoradiography. Metabolic labeling with
[32P]orthophosphate was done by incubating cells (in
100-mm dishes) with 5 ml of phosphate-free Dulbecco's modified
Eagle's medium containing 10% dialyzed fetal calf serum and 100 mM glutamine for 30 min followed by the addition of 50 µl
of normal medium and 250 µCi/ml [32P]orthophosphate.
After labeling for 5 h, keratins were immunoprecipitated from the
detergent-solubilized cells using mAb L2A1 and then analyzed by
preparative SDS-PAGE and Coomassie staining, followed by isolation of
the individual keratin-stained bands for peptide mapping.
 |
RESULTS |
Examination of K8 Ser-73 Phosphorylation by Mutational Analysis and
by in Vitro Phosphorylation--
We identified previously (31) K8
Ser-73 as a K8 phosphorylation site using what we termed a "reverse
immunologic" approach. This was aided by an antibody termed LJ4,
which was generated by immunizing mice with keratins that were purified
from okadaic acid-treated HT-29 cells. As shown previously (31) and
exemplified in Fig. 1A, mAb
LJ4 selectively recognizes the hyperphosphorylated and slightly slower
migrating K8 species termed HK8. The HK8 species are present in very
small amounts in exponentially growing HT-29 cells as determined by
immunoprecipitation with mAb L2A1, which recognizes the entire keratin
pool (31), but become markedly enriched after immunoprecipitation with
mAb LJ4. The LJ4 Ab recognizes HK8 exclusively (Fig. 1B,
lane 1), and its reactivity is abolished if Ser-73 is
mutated to an alanine (S73A) (Fig. 1B, lane 2).
However, LJ4 does recognize K8 S73D weakly (Fig. 1B,
lane 3), which migrates slightly faster than HK8 and a bit
slower than K8, such that LJ4 has almost equal binding intensity to the
barely visible Coomassie-stained HK8 as compared with the strongly
staining K8 S73D species (Fig. 1B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 1.
In vitro K8 phosphorylation by p38
or p42 kinases and mAb LJ4 reactivity with K8 Ser-73 mutants.
A, K8/18 immunoprecipitates from HT-29 cells were
prepared using anti-K18 mAb L2A1 or anti-K8 Ser(P)-73 mAb LJ4, followed
by SDS-PAGE, and then staining with Coomassie Blue. Note that mAb LJ4
preferentially recognizes the K8 Ser-73-phosphorylated species, HK8
(residual presence of K8 in lane 2 reflects the tetrameric
nature of keratins that may contain two K18, one K8, and one HK8
molecules per tetramer). B, BHK cells were
co-transfected with WT K18 and WT K8 or with WT K18 and the indicated
K8 phosphorylation mutants. K8/18 were precipitated with mAb L2A1 and
then analyzed by SDS-PAGE and Coomassie staining. Duplicate K8/18
immunoprecipitates were also separated by SDS-PAGE and then blotted
with mAb LJ4. Note that LJ4 reactivity is abolished in the S73A mutant
and is limited when blotted against the S73D mutant as compared with WT
K8 (see text). C, in vitro kinase assays
were performed using K8/18 immunoprecipitates that were obtained from
HT-29 cells. Precipitates were incubated with 5 µCi of
[ -32P]ATP, 20 µM ATP, and 1 unit of p38
or p42 kinase for 15 min followed by quenching with sample buffer then
SDS-PAGE analysis, Coomassie staining, and autoradiography
(autorad). i.p., immunoprecipitation.
|
|
We compared the in vitro phosphorylation of K8 by the
proline-directed MAPKs p38 and p42, given the sequence context of K8 Ser-73 (71LLSPL) and the previous observation (31) that K8
Ser-73 becomes phosphorylated during heat stress and apoptosis. As
shown in Fig. 1C, p38 kinase generates the radiolabeled HK8
species exclusively (a signature of Ser-73 phosphorylation), whereas
p42 kinase generates phosphorylated K8 and HK8 (K8 > HK8; compare
lanes 2 and 3). Mutation of the two major K8
phosphorylation sites, Ser-23 and Ser-431 (30), did not affect
formation of HK8 upon in vitro phosphorylation of K8/18
precipitates with p38 kinase (Fig.
2A, lanes 2 and
4). In contrast, mutation of K8 Ser-73 abolished formation
of the HK8 species and resulted in barely detectable K8 phosphorylation (Fig. 2A, lane 3) that is likely due to Ser-431
phosphorylation (the only other K8 potential proline-directed kinase
site, with the sequence 429LTSPG). The specificity of p38
kinase toward K8 Ser-73 is evident by the minimal formation of HK8 by
p42 kinase (Fig. 2B) and the nearly equal generation of
phospho-K8 and HK8 species by JNK (Fig. 2C). K8 Ser-23,
which is a major basally phosphorylated K8 site (30), is not
phosphorylated in vitro by any of the three tested MAPKs,
whereas K8 Ser-431 phosphorylation occurs by p42 and JNK but not by p38
kinase (Fig. 2). Hence, the in vitro kinase assays of WT and
mutant K8 immunoprecipitates indicate that both JNK and p42
phosphorylate K8 Ser-431 and Ser-73 relatively promiscuously, albeit to
varied levels, in marked contrast to the selectivity of p38 kinase to
the K8 Ser-73 site. In addition, phosphorylation of K8 Ser-73 does not
appear to impact on K8 Ser-431 phosphorylation and vice versa.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 2.
Phosphorylation of WT K8 and K8 mutants by
p38 kinase, p42 kinase, or JNK. BHK cells were co-transfected with
WT K18 and WT K8 or with WT K18 and one of three K8 phosphorylation
mutants (S23A, S73A, or S431A). Three days after transfection, K8/18
immunoprecipitates were obtained and then used in an in
vitro phosphorylation assay with the indicated kinases.
Precipitates were analyzed by SDS-PAGE, Coomassie staining, and then
autoradiography.
|
|
Evidence of in Vivo K8 Ser-73 Phosphorylation by a p38-like
Kinase--
Given the findings in Figs. 1 and 2, we explored the role
of p38 kinase as a potential in vivo K8 kinase by utilizing
known specific activators and inhibitors of p38 kinase and by comparing phosphopeptide maps of in vivo versus in
vitro p38-phosphorylated K8. As shown in Fig.
3A, activation of p38 kinase
in cultured HT-29 cells by An (42), as determined by p38
phosphorylation, is associated with rapid K8 Ser-73 phosphorylation.
Similarly, the alkylating agent MMS, a known p38 kinase and JNK
activator (43), generates the HK8 species in a dose- and
time-dependent fashion (Fig. 3B). Inhibition of
An-induced p38 kinase activation with the specific inhibitor compound
SB203580 abrogated K8 Ser-73 phosphorylation (Fig. 3C). In
contrast, inhibition of ERK1/2 kinase activation with compound PD98059
did not significantly affect K8 Ser-73 phosphorylation but did inhibit
K8 Ser-431 phosphorylation as determined by blotting with mAb 5B3 (Fig.
3D).

View larger version (37K):
[in this window]
[in a new window]
|
Fig. 3.
Modulation of K8 Ser-73 phosphorylation by
activation or inhibition of p38 kinase. A, HT-29
cells were treated with 0.1% Me2SO (0-h time point)
or with An (10 µg/ml) for the indicated times. Total lysates were
then prepared by solubilizing with SDS sample buffer. Lysates were
separated by SDS-PAGE, transferred to membranes, and then blotted with
anti-p38 and anti-phospho-p38 kinase antibodies or anti-K8 Ser(P)-73
mAb LJ4. B, HT-29 cells were incubated with MMS and
then harvested after the indicated time points, solubilized with 1%
Nonidet P-40, followed by immunoprecipitation with mAb L2A1. K8/18
precipitates were separated by SDS-PAGE and then stained with Coomassie
Blue or immunoblotted with mAb LJ4. Asterisks in lane
7 represent degraded K8 species. C and
D, HT-29 cells were preincubated for 1 h with 20 µM SB203580 (p38 kinase inhibitor) or 100 µM PD98059 (MAPK kinase inhibitor) followed by An
treatment for 2 h. K8/18 immunoprecipitates were obtained from 1%
Nonidet P-40-solubilized cells and then blotted with anti-K8 Ser(P)-73
(mAb LJ4) or anti-K8 Ser(P)-431 (mAb 5B3). K8 Ser-431 phosphorylation
is used as a control since we previously showed that this site becomes
phosphorylated upon epidermal growth factor stimulation and that it is
likely to be phosphorylated in vivo by p42 MAPK (30).
|
|
A comparison of the chymotryptic phosphopeptide maps of K8 and HK8 that
are isolated from in vivo phosphorylated cells shows that
HK8 differs from K8 by the presence of peptides 2-5 and by the absence
of the peptide highlighted by an unnumbered arrow (Fig.
4, a and b).
Interestingly, the phosphopeptide profile of HK8 that is generated by
in vitro phosphorylation of K8 with p38 kinase shows five
major peptides (Fig. 4c) that co-migrate with peptides 1-5
that are isolated from in vivo labeled HK8. This is
confirmed by mixing in vitro and in vivo labeled
K8 (Fig. 4d) and by mixing in vivo labeled HK8
with p38-labeled K8 (not shown). The five peptides are generated by
incomplete chymotryptic digestion (not shown). Taken together, these
results suggest that a p38-like kinase is likely to be involved,
in vivo, in K8 phosphorylation at Ser-73.

View larger version (74K):
[in this window]
[in a new window]
|
Fig. 4.
Phosphopeptide maps of in vitro
and in vivo phosphorylated K8 and HK8.
HT-29 cells were metabolically labeled with
32PO4 (250 µCi/ml) for 5 h (in the
presence or absence of 100 µg/ml of MMS to generate the HK8 species)
followed by immunoprecipitation of K8/18. K8 (from cells without MMS
treatment, a) and HK8 (from MMS-treated cells, b)
were individually isolated using preparative SDS-PAGE, followed by
chymotryptic phosphopeptide mapping. Alternatively, K8/18
immunoprecipitates were obtained from untreated HT-29 cells followed by
in vitro phosphorylation using [ -32P]ATP
and p38 kinase. K8 was separated by SDS-PAGE and then subjected to
chymotryptic peptide mapping (c). Equal counts of the
samples shown in a and c were also mixed and
analyzed (d). The x in the left lower
corners indicates the origin where samples were spotted onto thin
layer cellulose plates for two-dimensional separation using
electrophoresis (horizontal dimension) and then
chromatography (vertical dimension). Note that the
bracketed spots 2-5, which are not phosphorylated in K8
in vivo, are phosphorylated in vivo in HK8 and
are also generated after in vitro phosphorylation of K8 with
p38 kinase. The K8 peptide highlighted by an unnumbered
arrow becomes relatively dephosphorylated after MMS treatment in
HK8 (compare a with b) and in K8 (not
shown).
|
|
p38 Kinase Associates with K8/18 and Phosphorylates K8 Ser-73 in
Vivo and Binds to K8 in Vitro--
We further substantiated in
vivo p38 phosphorylation of K8 Ser-73 by comparing K8 Ser-73
phosphorylation in BHK cells transfected with FLAG-tagged human WT p38
or kinase-inactive p38 AF (Fig. 5A). The overexpressed p38
proteins are detected with anti-FLAG and anti-human p38 antibodies. As
anticipated, p38 AF is not recognized by phospho-p38 antibody, and K8
Ser-73 phosphorylation increases in BHK cells that overexpress WT but
not AF p38 (Fig. 5A, lanes 1-3). In addition, WT
and AF p38 kinases co-immunoprecipitate with K8/18 in transfected cells
(Fig. 5A, lanes 5 and 6);
arrowhead and arrows indicate degraded K8 or
apoptotic K18 fragments (44), respectively. Co-immunoprecipitation of
p38 with K8/18 was not observed in non-transfected cells
(e.g. HT-29 cells), which may be related to the high levels
of p38 kinase in transfected cells and the transient/weak nature of the
kinase-substrate interaction (not shown). The interaction of p38 kinase
with keratins was also confirmed using an in vitro overlay
assay. As shown in Fig. 5B, p38 kinase bound specifically to
K8 but not to K18. Taken together, these results support the conclusion
that p38 kinase associates with K8 and phosphorylates K8 Ser-73
in vivo.

View larger version (51K):
[in this window]
[in a new window]
|
Fig. 5.
Association of p38 kinase with K8/18
immunoprecipitates and specific binding of p38 kinase to K8 in
vitro. A, BHK cells were co-transfected
with WT K8/18 and one of the three constructs: vector, FLAG-tagged WT,
or AF p38. Transfected cells were solubilized with SDS-containing
sample buffer (total lysate) or with 1% Nonidet P-40 followed by
immunoprecipitation of K8/18. Total lysates and K8/18 precipitates were
analyzed by SDS-PAGE and stained with Coomassie Blue or transferred to
polyvinylidene difluoride membranes for immunoblotting with the
indicated antibodies. B, total lysate and a K8/18
immunoprecipitate (i.p.) were obtained from HT-29 cells and
then separated by SDS-PAGE and transferred to a membrane. The membrane
was incubated with purified p38 kinase, washed, and then blotted with
anti-p38 antibody as described under "Experimental
Procedures."
|
|
Effect of Disease-related Keratin Mutations on Keratin
Phosphorylation--
K8 Ser-73 is part of the sequence
68NQSLLSPL, a sequence that is identical in all type II
keratins (except for the Ser-73-equivalent residue which is substituted
by Ala in K7, Gln in K1-3, and Thr in K4-6; Ref. 31). Several of the
mutations that have been described for epidermal keratins result in
amino acid substitutions that potentially create a new, or remove a
potential, phosphorylation site. Given the known impact of
phosphorylation on keratin filament organization (9-11), it is
possible that such mutations could impact significantly on keratin
filament organization and disease pathogenesis, although such a
possibility has not been formally tested for any such mutation. To
address this, we focused on one such mutation (Leu-160
Pro of K1 in
a family of patients with epidermolytic hyperkeratosis (22)) that
occurs in the highly conserved Ser-73-containing domain of K8
(i.e. Leu-71 within 68NQSLLSPL of K8) by using
K8 as a model system (because K1 cDNA is not available). This
mutation generates a potential new proline-directed kinase-related site
at Ser-70 of K8 (Ser-159 of K1). As shown in Fig.
6A, the K8 L71P mutation
significantly increased K8 susceptibility to in vitro
phosphorylation by p38 (compare lane 1 with 2)
and p42 kinases (compare lane 3 with 4) but not
by JNK (compare lane 5 with 6). The K8 L71P
mutation also increased K8 phosphorylation in transfected cells after
exposure to okadaic acid (Fig. 6B). This was confirmed by
the presence of an HK8-like species in cells transfected with the K8
L71P but not with WT K8 as determined by Coomassie staining (Fig.
6B, compare lane 1 versus
2) and confirmed by immunoblotting with antibodies that
recognize the total and phospho-K8 pools (Fig. 6B,
lanes 3-6). No change was noted in K18 Ser-52
phosphorylation (Fig. 6B, lanes 9 and
10), which represents the major K18 phosphorylation site
(10), thereby indicating specificity of the increased phosphorylation
toward the mutant K8. Of note, the L71P K8 mutation inhibits binding of
the LJ4 antibody to K8 (Fig. 6B, lane 8) thereby
indicating that Leu-71 is part of the antibody epitope. Therefore,
disease-causing keratin mutations can indeed result in keratin
hyperphosphorylation as modeled by the K8 L71P mutation in
vitro and in vivo.

View larger version (56K):
[in this window]
[in a new window]
|
Fig. 6.
Effect of the L71P K8 mutation on K8
phosphorylation. A, BHK cells were co-transfected
with WT K18 and WT K8 or K8 L71P. After 3 days, cells were harvested
followed by immunoprecipitation of K8/18. Precipitates were subjected
to an in vitro kinase assay, followed by gel analysis and
autoradiography as described in Fig. 1 legend. B, cells
were transfected as in A. Just before harvesting, cells were
incubated with OA (1 µg/ml) for 2 h followed by
immunoprecipitation of K8/18. Precipitates were analyzed by SDS-PAGE
and then Coomassie staining or were analyzed by immunoblotting using
antibodies that recognize the total K8 pool, K8 Ser(P)-73, K8
Ser(P)-431, and K18 Ser(P)-52. Note that the K8 L71P mutation results
in hyperphosphorylation of K8 in vitro, using p38
kinase, and in transfected cells as determined by formation of the HK8
species.
|
|
Effect of K8 Ser-73
Ala, Ser-73
Asp, and Leu-71
Pro
Mutations on Keratin Filament Organization--
We tested the effect
of the K8 Ser-73
Ala, Ser-73
Asp, or Leu-71
Pro mutations
on K8/18 filament organization in transfected cells. Transient
co-transfection of NIH-3T3 cells with WT K18 and one of the four K8
constructs WT K8, K8 S73A, K8 S73D, or K8 L71P followed by
immunofluorescence staining of K8/18 showed a normal appearing and an
indistinguishable filament organization among the four K8 constructs
(shown only for WT and L71P K8 in Fig. 7,
a and e, respectively; with very similar profiles
for K8 S73A and S73D (not shown)). However, exposure of the transfected cells to okadaic acid unmasked significant differences in filament reorganization when comparing WT or S73D K8 with S73A K8 or when comparing WT K8 with L71P K8 (Fig. 7). For example and as shown in Fig.
7, okadaic acid resulted in 42 and 41% of the cells maintaining residual filaments in WT and S73D K8-transfected cells, respectively, whereas 61% of the cells transfected with S73A K8 had cells with intact filaments (a total of 120-180 cells were counted in three independent experiments, p < 0.05). Hence, S73D
rescues the filament reorganization defect caused by the S73A mutation,
likely due to the negative charge of the aspartate.

View larger version (119K):
[in this window]
[in a new window]
|
Fig. 7.
Immunofluorescence staining of NIH-3T3 cells
transfected with WT or mutant K8. NIH-3T3 cells were
co-transfected with WT K18 and one of the following K8 constructs: WT,
S73A, S73D, or L71P. Transfected cells were grown on coverslips, and 3 days after transfection they were further cultured in the presence
(+OA) or absence (control) of okadaic acid (1 µg/ml) for 2 h. Cells were then fixed with methanol and stained
using anti-K8 mAb M20. Note that OA results in the formation of a fine
punctate pattern preferentially in WT and S73D K8 transfectants but
less so in S73A transfectants. Also, note that OA-treated L71P
K8-transfected cells form large keratin-staining dots that are not seen
in the cells transfected with the other K8 constructs.
|
|
In the case of the L71P K8 mutant, nearly 10% of the cells with
collapsed filament (after exposure to okadaic acid) had prominent large
dots (Fig. 7f), whereas none of the cells transfected with any of the other K8 constructs manifested this phenotype. These large
dots likely represent coalesced smaller dots since longer exposure of
cells expressing WT K8 results in progression from a fine dot to a
large dot pattern (not shown). Taken together, these data suggest that
K8 Ser-73 phosphorylation is associated with keratin filament
destabilization and likely occurs to facilitate reorganization of the
keratin filaments, whereas the patient-associated K8 L71P mutation
results in an exaggerated keratin hyperphosphorylation response upon
okadaic acid stimulation with consequent amplified destabilization of
the keratin filament network.
 |
DISCUSSION |
K8 Ser-73 Is a Physiologic Substrate for a p38 MAPK--
The
temporal associations of K8 Ser-73 phosphorylation, as determined by
the signature formation of the HK8 species and by reactivity with mAb
LJ4, suggests that a stress-induced kinase is responsible for its
phosphorylation. We tested, in vitro, three candidate
kinases that are members of the MAPK superfamily, namely JNK, p42
(ERK1), and p38 kinase. Of these kinases, only p38 kinase phosphorylated K8 Ser-73 exclusively, based on HK8 formation (Fig. 1C and Fig. 2A), whereas JNK and p42 kinase
resulted in preferential phosphorylation of K8 (due to K8 Ser-431
phosphorylation) with some phosphorylation of the Ser-73 site (Fig.
1C; Fig. 2, B and C). Further support
for a physiologic role of p38 kinase in Ser-73 phosphorylation includes
the following: (i) association of K8 Ser-73 phosphorylation with states
that activate p38 kinase (e.g. An and MMS exposure of cells,
Fig. 3, A and B); (ii) generation of a
chymotryptic phosphopeptide pattern, upon in vitro
phosphorylation of K8 with p38 kinase, that is very similar to the
pattern of HK8 but not K8 in vivo phosphorylation (Fig. 4);
(iii) inhibition of K8 Ser-73 phosphorylation by the selective p38
kinase inhibitor SB203580 but not by PD98059 (Fig. 3, C and
D) which inhibits Erk1/2 kinase activation by inhibiting
MEK1/2 kinases; (iv) p38 kinase association with K8/18
immunoprecipitates and phosphorylation of K8 Ser-73 by p38 kinase in
transfected cells (Fig. 5A); and (v) specific binding of p38
kinase with K8 using an overlay assay (Fig. 5B). Hence, our
data strongly implicate K8 Ser-73 as a physiologic substrate for p38
kinase and adds K8 to the few known likely physiologic substrates of
p38 kinase that include MAPK-activated protein kinase-2 and ribosomal
S6 kinase-B (45).
Our assignment of K8 Ser-73 as a physiologic substrate of a p38 kinase
pertains in particular to p38
, although other p38-like kinases may
be involved given the growing list of related p38 kinases. The p38
kinase family (also called stress-activated protein kinase-2 (SAPK-2))
has several known members including p38
(SAPK-2
), p38
(SAPK-2
), p38
(SAPK-3), SAPK-4, and p38
(46). These kinases
share nearly 60-75% sequence identity and have some differences in
substrate specificity and in inhibition by pyridinylimidazole compounds
such as SB203580. In our case, we only tested the p38
kinase, which
is known to be inhibited by SB203580. It is likely that more than one
kinase does phosphorylate K8 Ser-73 in vivo since such
phosphorylation occurs during mitosis, a variety of cell stresses, and
apoptosis (10). To that end, p38 kinase activation is reported after a
variety of apoptotic stimuli and can also occur upon induction of
proliferation as noted for B cells (47, 48). In addition, Fas receptor
stimulation of HT-29 cells activates JNK selectively, rather than p38
kinase, and results in phosphorylation of K8 Ser-73 (53).
Disease-causing Keratins Mutations May Modulate Keratin
Phosphorylation--
Several epidermal keratin mutations have been
described at sites that may potentially introduce or remove a
phosphorylation site and hence may affect disease pathogenesis by
modulation of keratin phosphorylation upon the appropriate cell
stimulation (12, 13, 15-17). However, this potential of
mutation-associated modulation of phosphorylation has not been formally
tested for any of these mutations. Given that one such mutation in K1
(L160P) occurs at the highly conserved K8 Ser-73-like motif (K8 Leu-71 in 68NQSLLSPL is the equivalent Leu
(boldface letters indicate conserved residues in all type II
keratins)), we tested in K8 the effect of the K1 equivalent L71P
mutation. This mutation resulted in K8 hyperphosphorylation, likely due
to phosphorylation at the newly generated proline-directed kinase site
in 68NQSPLSPL. Hyperphosphorylation of K8 L71P
was confirmed in cultured cells after exposure to okadaic acid and
in vitro by p38 kinase phosphorylation (Fig. 6) and was
associated with abnormal keratin filament reorganization (Fig. 7).
Hence, our results support the conclusion that disease-causing keratin
mutations can indeed generate abnormally phosphorylated keratins in a
fashion that will predictably depend on the context of the mutation. At least in some cases, such modulation of keratin phosphorylation can
alter keratin filament organization (Fig.
8) in response to physiologic and
nonphysiologic hyperphosphorylating stimuli.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 8.
Proposed model for the significance of K8
Ser-73 phosphorylation and the potential impact of disease-causing
phosphorylation-modulating keratin mutations. The exchange between
the basal K8/18 filaments and the progenitor soluble filament pool is
likely to be K8 Ser-73-independent due to the absence of any detectable
basal K8 Ser-73 phosphorylation. Stimulation of cells, as may occur
during cell stress or apoptosis, results in K8 Ser-73 phosphorylation
via p38 kinase and in "normal" keratin filament reorganization
(with increased keratin solubility), which becomes limited upon a K8
Ser-73 Ala mutation. A K8 Ser-73 Asp mutation rescues the
filament reorganization defect that is caused by blocking Ser-73
phosphorylation. However, disease-causing mutations, such as the
K1-like mutation that was introduced into K8 (L71P), can cause a
hyper-hyperphosphorylated keratin state (upon stimulation) with
subsequent abnormal keratin filament reorganization (indicated by
large dots). Disease-causing mutations may also result in
abnormal filament reorganization due to a hypophosphorylated state, as
would be the case for a K8 S73A-like mutation.
|
|
We used okadaic acid as a model system for the induction of generalized
hyperphosphorylation, including the K8 Ser-73 site that undergoes
phosphorylation in the presence of OA (31), since we were not able to
visualize with confidence enough mitotic cells in our transient
transfection system (not shown). Of note, phosphatase inhibitors, such
as okadaic acid and microcystin, are major hepatotoxins in animals
(49-51) and in humans (52). Therefore, despite their generalized
effects, the use of such compounds in cultured cells provides a
relevant and sensitive filament reorganization model system.
K8 Ser-73 Phosphorylation Plays an Essential Role in Keratin
Filament Organization--
One unique feature of the K8 Ser-73
phosphorylation site, as contrasted with other known K8 and K18
phosphorylation sites, is its near-absolute on/off property whereas
other phosphorylation sites manifest up/down modulation of a basal
phosphorylation state depending on the stimulus (10). This on/off
property and the reversible induction of this phosphorylation suggest
important biologic role(s) for this modification that represents the
convergence of several contexts (e.g. stress, apoptosis, and
mitosis; Ref. 31) that include p38 kinase activation and subsequent K8
Ser-73 phosphorylation. One common feature for these differing biologic contexts is the observed keratin filament reorganization that is
associated with these processes. The data presented herein suggest a
unique function for K8 Ser-73 phosphorylation, which is to allow
keratin filaments to reorganize. The evidence for this role is the
absence of a keratin-assembly defect upon transient transfection of a
K8 S73A mutant but the unmasking of a phenotype upon exposure to
OA-mediated hyperphosphorylating conditions (Fig. 7). Furthermore, the
K8 S73D mutation rescues the S73A phenotype thereby supporting the role
of the phosphoserine moiety at that site. Hence the aspartate
substitution mimics the phosphate of K8 Ser(P)-73 biologically by
rescuing the K8 S73A phenotype (Fig. 7) and biochemically by altering
the migration pattern in SDS-PAGE gels from K8 to HK8-like (Fig.
1B).
Another unique feature of the K8 Ser(P)-73 species is their
distribution among various cellular compartments, as compared with
other K8 and K18 species that are phosphorylated at other sites. For
example, K8/18 are found in increasing abundance in the sequentially
isolated cytosolic, Nonidet P-40, Emp, and then post-Emp solubilized
fractions (10, 25). Interestingly, the HK8 species are distributed
nearly uniformly throughout these fractions, whereas keratins that are
phosphorylated on K18 Ser-52 or K18 Ser-33 are preferentially found in
the cytosolic and Nonidet P-40-containing fractions (10, 26). This
implies that keratin species that are typically cytoskeletal and
insoluble (K8 Ser-73 state) become reorganized in a fashion that is
associated with p38 kinase activation (and phosphorylation at other
keratin sites) to favor generation of the K8 Ser(P)-73 state and
distribution within the different cellular compartments in order to
facilitate filament reorganization (Fig. 8).
 |
ACKNOWLEDGEMENTS |
We are indebted to Dr. John Lee for supplying
SB203580 and to Kris Morrow for preparing the figures.
 |
FOOTNOTES |
*
This work was supported by National Institutes of Health
Grant DK52951 and Digestive Disease Center Grant DK56339 and by a Department of Veterans Affairs Career Development award.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom reprint requests should be addressed.
§
To whom correspondence should be addressed: Palo Alto Veterans
Affairs Medical Center, 3801 Miranda Ave., 154J, Palo Alto, CA 94304.
Published, JBC Papers in Press, January 11, 2002, DOI 10.1074/jbc.M107623200
 |
ABBREVIATIONS |
The abbreviations used are:
K, keratin;
Ab, antibody;
An, anisomycin;
Emp, Empigen BB;
IF, intermediate filament(s);
mAb, monoclonal antibody;
MAPK, mitogen-activated protein
kinase;
MMS, methyl methanesulfonate;
OA, okadaic acid;
PBS, phosphate-buffered saline;
Ser(P)-, phosphoserine;
SAPK, stress-activated protein kinase;
WT, wild-type;
BHK, baby hamster
kidney.
 |
REFERENCES |
| 1.
|
Calnek, D.,
and Quaroni, A.
(1993)
Differentiation
53,
95-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Moll, R.,
Franke, W. W.,
Schiller, D. L.,
Geiger, B.,
and Krepler, R.
(1982)
Cell
31,
11-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Moll, R.,
Schiller, D. L.,
and Franke, W. W.
(1990)
J. Cell Biol.
111,
567-580[Abstract/Free Full Text]
|
| 4.
|
Moll, R.,
Zimbelmann, R.,
Goldschmidt, M. D.,
Keith, M.,
Laufer, J.,
Kasper, M.,
Koch, P. J.,
and Franke, W. W.
(1993)
Differentiation
53,
75-93[Medline]
[Order article via Infotrieve]
|
| 5.
|
Herrmann, H.,
and Aebi, U.
(2000)
Curr. Opin. Cell Biol.
12,
79-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Fuchs, E.,
and Weber, K.
(1994)
Annu. Rev. Biochem.
63,
345-382[Medline]
[Order article via Infotrieve]
|
| 7.
|
Eriksson, J. E.,
Opal, P.,
and Goldman, R. D.
(1992)
Curr. Opin. Cell Biol.
4,
99-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Inagaki, M.,
Matsuoka, Y.,
Tsujimura, K.,
Ando, S.,
Tokui, T.,
Takahashi, T.,
and Inagaki, N.
(1996)
Bioessays
18,
481-487[CrossRef]
|
| 9.
|
Ku, N. O.,
Liao, J.,
Chou, C. F.,
and Omary, M. B.
(1996)
Cancer Metastasis Rev.
15,
429-444[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Omary, M. B., Ku, N. O.,
Liao, J.,
and Price, D.
(1998)
Subcell. Biochem.
31,
105-140[Medline]
[Order article via Infotrieve]
|
| 11.
|
Coulombe, P. A.,
and Omary, M. B.
(2002)
Curr. Opin. Cell Biol.
14,
110-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Omary, M. B.,
and Ku, N. O.
(1997)
Hepatology
25,
1043-1048[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Steinert, P. M.,
and Bale, S. J.
(1993)
Trends Genet.
9,
280-284[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ku, N. O.,
Gish, R.,
Wright, T. L.,
and Omary, M. B.
(2001)
N. Engl. J. Med.
344,
1580-1587[Abstract/Free Full Text]
|
| 15.
|
Irvine, A. D.,
and McLean, W. H.
(1999)
Br. J. Dermatol.
140,
815-828[Medline]
[Order article via Infotrieve]
|
| 16.
|
Fuchs, E.,
and Cleveland, D. W.
(1998)
Science
279,
514-519[Abstract/Free Full Text]
|
| 17.
|
Fuchs, E.,
and Coulombe, P. A.
(1992)
Cell
69,
899-902[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Marceau, N.,
Loranger, A.,
Gilbert, S.,
Daigle, N.,
and Champetier, S.
(2001)
Biochem. Cell Biol.
79,
543-555[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Omary, M. B., Ku, N. O.,
and Toivola, D. M.
(2002)
Hepatology
35,
251-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 20.
|
Magin, T. M.,
Hesse, M.,
and Schroder, R.
(2000)
Protoplasma
211,
140-150[CrossRef]
|
| 21.
|
Yano, T.,
Tokui, T.,
Nishi, Y.,
Nishizawa, K.,
Shibata, M.,
Kikuchi, K.,
Tsuiki, S.,
Yamauchi, T.,
and Inagaki, M.
(1991)
Eur. J. Biochem.
197,
281-290[Medline]
[Order article via Infotrieve]
|
| 22.
|
Chipev, C. C.,
Korge, B. P.,
Markova, N.,
Bale, S. J.,
DiGiovanna, J. J.,
Compton, J. G.,
and Steinert, P. M.
(1992)
Cell
70,
821-828[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Muller, F. B.,
Kuster, W.,
Bruckner-Tuderman, L.,
and Korge, B. P.
(1998)
J. Invest. Dermatol.
111,
900-902[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Chou, C. F.,
Riopel, C. L.,
Rott, L. S.,
and Omary, M. B.
(1993)
J. Cell Sci.
105,
433-444[Abstract]
|
| 25.
|
Liao, J.,
and Omary, M. B.
(1996)
J. Cell Biol.
133,
345-357[Abstract/Free Full Text]
|
| 26.
|
Ku, N. O.,
Liao, J.,
and Omary, M. B.
(1998)
EMBO J.
17,
1892-1906[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Zhou, X.,
Liao, J., Hu, L.,
Feng, L.,
and Omary, M. B.
(1999)
J. Biol. Chem.
274,
12861-12866[Abstract/Free Full Text]
|
| 28.
|
Ku, N. O.,
Michie, S. A.,
Soetikno, R. M.,
Resurreccion, E. Z.,
Broome, R. L.,
and Omary, M. B.
(1998)
J. Cell Biol.
143,
2023-2032[Abstract/Free Full Text]
|
| 29.
|
Ku, N. O.,
Zhou, X.,
Toivola, D. M.,
and Omary, M. B.
(1999)
Am. J. Physiol.
277,
G1108-G1137[Medline]
[Order article via Infotrieve]
|
| 30.
|
Ku, N. O.,
and Omary, M. B.
(1997)
J. Biol. Chem.
272,
7556-7564[Abstract/Free Full Text]
|
| 31.
|
Liao, J., Ku, N. O.,
and Omary, M. B.
(1997)
J. Biol. Chem.
272,
17565-17573[Abstract/Free Full Text]
|
| 32.
|
Davis, R. J.
(2000)
Cell
103,
239-252[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Kyriakis, J. M.,
and Avruch, J.
(2001)
Physiol. Rev.
81,
807-869[Abstract/Free Full Text]
|
| 34.
|
Ono, K.,
and Han, J.
(2000)
Cell. Signal.
12,
1-13[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Seger, R.,
and Krebs, E. G.
(1995)
FASEB J.
9,
726-735[Abstract]
|
| 36.
|
Liao, J.,
Lowthert, L. A., Ku, N. O.,
Fernandez, R.,
and Omary, M. B.
(1995)
J. Cell Biol.
131,
1291-1301[Abstract/Free Full Text]
|
| 37.
|
Laemmli, U. K.
(1970)
Nature
227,
680-685[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Han, J.,
Lee, J. D.,
Bibbs, L.,
and Ulevitch, R. J.
(1994)
Science
265,
808-811[Abstract/Free Full Text]
|
| 39.
|
Towbin, H.,
Staehelin, T.,
and Gordon, J.
(1979)
Proc. Natl. Acad. Sci. U. S. A.
76,
4350-4354[Abstract/Free Full Text]
|
| 40.
|
Boyle, W. J.,
van der Geer, P.,
and Hunter, T.
(1991)
Methods Enzymol.
201,
110-149[Medline]
[Order article via Infotrieve]
|
| 41.
|
Liao, J.,
Lowthert, L. A.,
Ghori, N.,
and Omary, M. B.
(1995)
J. Biol. Chem.
270,
915-922[Abstract/Free Full Text]
|
| 42.
|
Cano, E.,
Doza, Y. N.,
Ben-Levy, R.,
Cohen, P.,
and Mahadevan, L. C.
(1996)
Oncogene
12,
805-812[Medline]
[Order article via Infotrieve]
|
| 43.
|
Wilhelm, D.,
Bender, K.,
Knebel, A.,
and Angel, P.
(1997)
Mol. Cell. Biol.
17,
4792-4800[Abstract]
|
| 44.
|
Ku, N. O.,
and Omary, M. B.
(2001)
J. Biol. Chem.
276,
26792-26798[Abstract/Free Full Text]
|
| 45.
|
Pierrat, B.,
Correia, J. S.,
Mary, J. L.,
Tomas-Zuber, M.,
and Lesslauer, W.
(1998)
J. Biol. Chem.
273,
29661-29671[Abstract/Free Full Text]
|
| 46.
|
Hu, M. C.,
Wang, Y. P.,
Mikhail, A.,
Qiu, W. R.,
and Tan, T. H.
(1999)
J. Biol. Chem.
274,
7095-7102[Abstract/Free Full Text]
|
| 47.
|
Craxton, A.,
Otipoby, K. L.,
Jiang, A.,
and Clark, E. A.
(1999)
Adv. Immunol.
73,
79-152[Medline]
[Order article via Infotrieve]
|
| 48.
|
Deschesnes, R. G.,
Huot, J.,
Valerie, K.,
and Landry, J.
(2001)
Mol. Biol. Cell
12,
1569-1582[Abstract/Free Full Text]
|
| 49.
|
Ding, W. X.,
Shen, H. M.,
and Ong, C. N.
(2000)
Hepatology
32,
547-555[CrossRef][Medline]
[Order article via Infotrieve]
|
| 50.
|
Hooser, S. B.
(2000)
Toxicol. Pathol.
28,
726-733[Abstract/Free Full Text]
|
| 51.
|
Runnegar, M. T.,
Kong, S.,
and Berndt, N.
(1993)
Am. J. Physiol.
265,
G224-G230[Medline]
[Order article via Infotrieve]
|
| 52.
|
Jochimsen, E. M.,
Carmichael, W. W., An, J. S.,
Cardo, D. M.,
Cookson, S. T.,
Holmes, C. E.,
Antunes, M. B.,
de Melo Filho, D. A.,
Lyra, T. M.,
Barreto, V. S.,
Azevedo, S. M.,
and Jarvis, W. R.
(1998)
N. Engl. J. Med.
338,
873-878[Abstract/Free Full Text]
|
| 53.
|
He, T.,
Stepulak, A.,
Holmstrom, T. H.,
Omary, M. B.,
and Eriksson, J. E.
(2002)
J. Biol. Chem.
277,
10767-10774[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Woll, R. Windoffer, and R. E. Leube
p38 MAPK-dependent shaping of the keratin cytoskeleton in cultured cells
J. Cell Biol.,
June 21, 2007;
177(5):
795 - 807.
[Abstract]
[Full Text]
[PDF]
|
 |
|